TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Brief Summary: To evaluate the efficacy and safety of lumacaftor in combination with ivacaftor in subjects aged 6 Through 11 years with cystic fibrosis (CF), homozygous for the F508del CF transmembrane conductance regulator (CFTR) mutation


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg Ivacaftor q12h; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): 150 mg Ivacaftor q12h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: TEZ/IVA; Type: ACTIVE_COMPARATOR; Interventions: Drug: TEZ/IVA, Drug: IVA, Drug: Placebo | Arm Label: VX-445/TEZ/IVA TC; Type: EXPERIMENTAL; Interventions: Drug: VX-445/TEZ/IVA, Drug: IVA, Drug: Placebo | Intervention Type: DRUG; Name: VX-445/TEZ/IVA; Assigned to Arm(s): VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: TEZ/IVA; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): TEZ/IVA, VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): VX-445/TEZ/IVA TC
C: Arm Label: VX-659/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-659/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: VX-659/TEZ/IVA; Assigned to Arm(s): VX-659/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): VX-659/TEZ/IVA
D: Arm Label: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-809, Drug: VX-770 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): LUM/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VX-770; Assigned to Arm(s): LUM/IVA

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Brief Summary: To evaluate the efficacy and safety of lumacaftor in combination with ivacaftor in subjects aged 6 Through 11 years with cystic fibrosis (CF), homozygous for the F508del CF transmembrane conductance regulator (CFTR) mutation


Options:
A: Arm Label: Ivacaftor Group A; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 25 mg/75 mg | Arm Label: Ivacaftor Group B; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 75 mg/150 mg | Arm Label: Ivacaftor Group C; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 150 mg or 250 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ivacaftor 25 mg/75 mg; Assigned to Arm(s): Ivacaftor Group A | Intervention Type: DRUG; Name: Ivacaftor 75 mg/150 mg; Assigned to Arm(s): Ivacaftor Group B | Intervention Type: DRUG; Name: Ivacaftor 150 mg or 250 mg; Assigned to Arm(s): Ivacaftor Group C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-809, Drug: VX-770 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): LUM/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VX-770; Assigned to Arm(s): LUM/IVA
C: Arm Label: sodium chloride 6%; Type: EXPERIMENTAL; Interventions: Drug: sodium chloride 6% | Arm Label: sodium chloride 0,9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride 0,9% | Intervention Type: DRUG; Name: sodium chloride 6%; Assigned to Arm(s): sodium chloride 6% | Intervention Type: DRUG; Name: sodium chloride 0,9%; Assigned to Arm(s): sodium chloride 0,9%
D: Arm Label: Dornase alfa; Type: EXPERIMENTAL; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Arm Label: isotonic saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Intervention Type: DRUG; Name: Dornase alfa (Pulmozyme); Assigned to Arm(s): Dornase alfa, isotonic saline | Intervention Type: DRUG; Name: isotonic saline; Assigned to Arm(s): Dornase alfa, isotonic saline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Brief Summary: To evaluate the efficacy and safety of lumacaftor in combination with ivacaftor in subjects aged 6 Through 11 years with cystic fibrosis (CF), homozygous for the F508del CF transmembrane conductance regulator (CFTR) mutation


Options:
A: Arm Label: Dornase alfa; Type: EXPERIMENTAL; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Arm Label: isotonic saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Intervention Type: DRUG; Name: Dornase alfa (Pulmozyme); Assigned to Arm(s): Dornase alfa, isotonic saline | Intervention Type: DRUG; Name: isotonic saline; Assigned to Arm(s): Dornase alfa, isotonic saline
B: Arm Label: sodium chloride 6%; Type: EXPERIMENTAL; Interventions: Drug: sodium chloride 6% | Arm Label: sodium chloride 0,9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride 0,9% | Intervention Type: DRUG; Name: sodium chloride 6%; Assigned to Arm(s): sodium chloride 6% | Intervention Type: DRUG; Name: sodium chloride 0,9%; Assigned to Arm(s): sodium chloride 0,9%
C: Arm Label: Ivacaftor Group A; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 25 mg/75 mg | Arm Label: Ivacaftor Group B; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 75 mg/150 mg | Arm Label: Ivacaftor Group C; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 150 mg or 250 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ivacaftor 25 mg/75 mg; Assigned to Arm(s): Ivacaftor Group A | Intervention Type: DRUG; Name: Ivacaftor 75 mg/150 mg; Assigned to Arm(s): Ivacaftor Group B | Intervention Type: DRUG; Name: Ivacaftor 150 mg or 250 mg; Assigned to Arm(s): Ivacaftor Group C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-809, Drug: VX-770 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): LUM/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VX-770; Assigned to Arm(s): LUM/IVA

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ridge Preservation Following Tooth Extraction Using Mineralized Freeze-Dried Bone Allograft Compared to PUROS Mineralized Bone Allograft
Brief Summary: The study is a 2-arm, parallel-design, randomized, prospective clinical trial designed to examine histologic wound healing following ridge preservation using bone allograft that has been prepared by either freeze-drying or via a non-freeze-dried solvent process.This entire protocol involves procedures that are standard care. All materials are FDA-approved materials being used in an FDA-approved manner. The test group subjects will have extraction sockets grafted with a cancellous non-freeze-dried bone allograft (called PUROS graft). This test group will be compared to an active control group using cancellous freeze-dried bone allograft (called FDBA). The null hypothesis is that there will be no significant difference in formation of new vital bone between treatment groups (primary outcome).

Each subject will provide a single non-molar tooth site for study treatment. After tooth extraction, the graft material will be placed and covered by a resorbable collagen membrane. Following 3 months of healing, the dental implant will be place, at which time a core of bone will be removed from the site as part of the preparation for the implant. The core biopsy will then be evaluated for the primary histologic outcome of % vital bone formation and secondary histologic outcome of % residual graft material.


Options:
A: Arm Label: Test: Porcine Xenograft (Zcore); Type: EXPERIMENTAL; Interventions: Device: Porcine Xenograft (Zcore) | Arm Label: Active Control: Bovine Xenograft (Bio-Oss); Type: ACTIVE_COMPARATOR; Interventions: Device: Bovine Xenograft (Bio-Oss) | Intervention Type: DEVICE; Name: Porcine Xenograft (Zcore); Assigned to Arm(s): Test: Porcine Xenograft (Zcore) | Intervention Type: DEVICE; Name: Bovine Xenograft (Bio-Oss); Assigned to Arm(s): Active Control: Bovine Xenograft (Bio-Oss)
B: Arm Label: PUROS (Non-Freeze-Dried bone allograft); Type: EXPERIMENTAL; Interventions: Device: PUROS (Ridge Preservation bone grafting surgery) | Arm Label: FDBA (Freeze-Dried bone allograft); Type: ACTIVE_COMPARATOR; Interventions: Device: FDBA (Ridge Preservation bone grafting surgery) | Intervention Type: DEVICE; Name: PUROS (Ridge Preservation bone grafting surgery); Assigned to Arm(s): PUROS (Non-Freeze-Dried bone allograft) | Intervention Type: DEVICE; Name: FDBA (Ridge Preservation bone grafting surgery); Assigned to Arm(s): FDBA (Freeze-Dried bone allograft)
C: Arm Label: Ridge preservation; Type: OTHER; Interventions: Procedure: Ridge preservation | Arm Label: No ridge preservation; Type: OTHER; Interventions: Procedure: Ridge preservation | Intervention Type: PROCEDURE; Name: Ridge preservation; Assigned to Arm(s): No ridge preservation, Ridge preservation
D: Arm Label: Placing OSSIX-Plus in Extraction Site; Type: EXPERIMENTAL; Interventions: Device: OSSIX-Plus | Intervention Type: DEVICE; Name: OSSIX-Plus; Assigned to Arm(s): Placing OSSIX-Plus in Extraction Site

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Physiotherapy Program in Patients Hospitalized Due to Pneumonia
Brief Summary: Acute respiratory infections are the fourth cause of hospitalization in elderly. Various studies have examined the impact of hospitalization in patients with respiratory pathology, showing the need of interventions in order to reduce the impact of hospitalization. The objective of this study is to examine whether a physical therapy intervention can reduce impairment in patients hospitalized due to pneumonia.


Options:
A: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: Experimental group | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group | Intervention Type: OTHER; Name: Experimental group; Assigned to Arm(s): Experimental group | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group
B: Arm Label: Intensive physical therapy; Type: EXPERIMENTAL; Interventions: Procedure: intensive physical therapy | Arm Label: control group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: control group | Intervention Type: PROCEDURE; Name: intensive physical therapy; Assigned to Arm(s): Intensive physical therapy | Intervention Type: PROCEDURE; Name: control group; Assigned to Arm(s): control group
C: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: Physiotherapy program | Arm Label: Control group; Type: OTHER; Interventions: Drug: cephalosporin with or without erythromycin | Intervention Type: DRUG; Name: cephalosporin with or without erythromycin; Assigned to Arm(s): Control group | Intervention Type: OTHER; Name: Physiotherapy program; Assigned to Arm(s): Experimental group
D: Arm Label: Resistance training and protein; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein, Other: Resistance training, Dietary Supplement: Vitamin D | Arm Label: Resistance training and placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo, Other: Resistance training, Dietary Supplement: Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein; Assigned to Arm(s): Resistance training and protein | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Resistance training and placebo | Intervention Type: OTHER; Name: Resistance training; Assigned to Arm(s): Resistance training and placebo, Resistance training and protein | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Resistance training and placebo, Resistance training and protein

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Physiotherapy Program in Patients Hospitalized Due to Pneumonia
Brief Summary: Acute respiratory infections are the fourth cause of hospitalization in elderly. Various studies have examined the impact of hospitalization in patients with respiratory pathology, showing the need of interventions in order to reduce the impact of hospitalization. The objective of this study is to examine whether a physical therapy intervention can reduce impairment in patients hospitalized due to pneumonia.


Options:
A: Arm Label: Physiotherapy+conventional treatment; Type: EXPERIMENTAL; Interventions: Other: Physiotherapy+conventional treatment | Arm Label: Conventional treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conventional treatment | Intervention Type: OTHER; Name: Physiotherapy+conventional treatment; Assigned to Arm(s): Physiotherapy+conventional treatment | Intervention Type: DRUG; Name: Conventional treatment; Assigned to Arm(s): Conventional treatment
B: Arm Label: Osteopathic Manipulative Treatment; Type: EXPERIMENTAL; Interventions: Procedure: Osteopathic Manipulative Treatment | Arm Label: Light-touch Treatment; Type: SHAM_COMPARATOR; Interventions: Procedure: Light-touch Treatment | Arm Label: Conventional Care Only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Osteopathic Manipulative Treatment; Assigned to Arm(s): Osteopathic Manipulative Treatment | Intervention Type: PROCEDURE; Name: Light-touch Treatment; Assigned to Arm(s): Light-touch Treatment
C: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: Experimental group | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group | Intervention Type: OTHER; Name: Experimental group; Assigned to Arm(s): Experimental group | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group
D: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: Physiotherapy program | Arm Label: Control group; Type: OTHER; Interventions: Drug: cephalosporin with or without erythromycin | Intervention Type: DRUG; Name: cephalosporin with or without erythromycin; Assigned to Arm(s): Control group | Intervention Type: OTHER; Name: Physiotherapy program; Assigned to Arm(s): Experimental group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Southwest Health Extension Partnership to Enhance Research Dissemination
Brief Summary: Heart disease and strokes cause one in three deaths reported each year in the United States. Primary care practices need to implement new research findings that help decrease patients' risk for heart disease and stroke. This project will help to build primary care practice capacity for quality improvement and change management in small and medium size primary care practices in Colorado and New Mexico. This project will also help practices implement patient-centered outcomes research findings.


Options:
A: Arm Label: Standard practice transformation support; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard practice transformation support | Arm Label: Enhanced practice transformation support; Type: EXPERIMENTAL; Interventions: Other: Enhanced practice transformation support | Intervention Type: OTHER; Name: Enhanced practice transformation support; Assigned to Arm(s): Enhanced practice transformation support | Intervention Type: OTHER; Name: Standard practice transformation support; Assigned to Arm(s): Standard practice transformation support
B: Arm Label: Early implementation practices; Type: ACTIVE_COMPARATOR; Interventions: Other: Implementation of the MOHR assessment in primary care workflow | Arm Label: Delayed implementation practices; Type: OTHER; Interventions: Other: Implementation of the MOHR assessment in primary care workflow | Intervention Type: OTHER; Name: Implementation of the MOHR assessment in primary care workflow; Assigned to Arm(s): Delayed implementation practices, Early implementation practices
C: Arm Label: Shared decision-making program; Type: EXPERIMENTAL; Interventions: Other: Shared decision-making program | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Shared decision-making program; Assigned to Arm(s): Shared decision-making program | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care
D: Arm Label: Intervention CBOs; Type: EXPERIMENTAL; Interventions: Other: Co-developed IT intervention | Arm Label: Control CBOs; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Co-developed IT intervention; Assigned to Arm(s): Intervention CBOs

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Single and Repeated Dose of Vaginal Misoprostol for the Treatment of Early Pregnancy Failure - a Randomized Clinical Trial
Brief Summary: A randomised controlled trial assessing the efficacy of single versus repeated dose of vaginal misoprostol for the treatment of early pregnancy failure.


Options:
A: Arm Label: surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): surgery
B: Arm Label: Misoprostol group; Type: OTHER; Interventions: Drug: Misoprostol | Arm Label: Expectant group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol group
C: Arm Label: Misoprostol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Misoprostol and Mifepristone; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone, Drug: Misoprostol | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): Misoprostol and Mifepristone | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, Misoprostol and Mifepristone
D: Arm Label: Single dose group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Repeated dose group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Repeated dose group, Single dose group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Single and Repeated Dose of Vaginal Misoprostol for the Treatment of Early Pregnancy Failure - a Randomized Clinical Trial
Brief Summary: A randomised controlled trial assessing the efficacy of single versus repeated dose of vaginal misoprostol for the treatment of early pregnancy failure.


Options:
A: Arm Label: Single dose group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Repeated dose group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Repeated dose group, Single dose group
B: Arm Label: pitocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: mifepristone and oxytocin | Arm Label: misopristol; Type: ACTIVE_COMPARATOR; Interventions: Drug: mifepristone and misopristol | Intervention Type: DRUG; Name: mifepristone and misopristol; Assigned to Arm(s): misopristol | Intervention Type: DRUG; Name: mifepristone and oxytocin; Assigned to Arm(s): pitocin
C: Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Manual vacuum aspiration (MVA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery Manual vacuum aspiration (MVA) | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: surgery Manual vacuum aspiration (MVA); Assigned to Arm(s): Manual vacuum aspiration (MVA)
D: Arm Label: surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): surgery

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Single and Repeated Dose of Vaginal Misoprostol for the Treatment of Early Pregnancy Failure - a Randomized Clinical Trial
Brief Summary: A randomised controlled trial assessing the efficacy of single versus repeated dose of vaginal misoprostol for the treatment of early pregnancy failure.


Options:
A: Arm Label: Misoprostol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Misoprostol and Mifepristone; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone, Drug: Misoprostol | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): Misoprostol and Mifepristone | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, Misoprostol and Mifepristone
B: Intervention Type: DRUG; Name: mifepristone and misoprostol; Assigned to Arm(s): N/A
C: Arm Label: Buccal; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol, Device: Semi-quantitative pregnancy test | Arm Label: Sublingual; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol, Device: Semi-quantitative pregnancy test | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Buccal, Sublingual | Intervention Type: DEVICE; Name: Semi-quantitative pregnancy test; Assigned to Arm(s): Buccal, Sublingual
D: Arm Label: Single dose group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Repeated dose group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Repeated dose group, Single dose group

Answer: D